Industry

Healthcare & Pharma.

Name: Anil Arora & Co.
Address: First Floor, K-359, opp. Water Tank, near Emerald Mall, Ashiyana Colony, Sector K, LDA Colony, Lucknow, Uttar Pradesh, 226012, IN
Telephone: +91 522 407 1089

Drug-licensing interface, R&D weighted deduction, PE / VC funding readiness, ESOP design, and MedTech valuations for hospitals, pharma, and diagnostic businesses.

Sector context

The regulatory landscape, the compliance rhythm, and the questions that come up at audit.

Anil Arora & Co. works with hospitals, pharma manufacturers, diagnostic chains, and MedTech startups, which sit across two very different regulatory worlds. On the operating side: Drugs & Cosmetics Act licensing (Forms 20, 21, and the wholesale and manufacturing variants) administered by the state FDA, NPPA price-control compliance for scheduled formulations, the Clinical Establishments Act registration regime in adopting states, and — for diagnostic labs — NABL / NABH accreditation. GST sits awkwardly on this sector: healthcare services by a clinical establishment are largely exempt under Notification 12/2017-CT(R), but the input tax credit on capex (medical equipment, hospital construction, IT systems) is consequently blocked, which has a material working-capital effect.

On the corporate-finance side, this sector has unusually active deal flow. R&D-heavy pharma and MedTech businesses claim weighted deduction under Section 35(2AB) where eligible, with the DSIR-recognised in-house R&D facility paperwork to match. ESOP design for clinical and engineering talent, Rule 11UA valuations for PE / VC rounds, Section 56(2)(viib) angel-tax positioning for medtech startups, and exit-readiness work (vendor due diligence, working-capital normalisation, quality of earnings) are all recurring engagements.

How we help

Specific touch-points for healthcare & pharma.

The bullets below describe recurring service touch-points in this sector. An engagement typically draws from a subset; we scope the right combination once we understand the business.

GST advisory on the healthcare-services exemption, blocked input tax credit on capex, and rate analysis for pharma manufacturers and traders
R&D weighted deduction under Section 35(2AB), DSIR recognition paperwork, and Form 3CL certification
Statutory and tax audit of hospitals, pharma manufacturers, diagnostic chains, and MedTech entities
PE / VC funding readiness — financial models, data rooms, vendor due diligence, and quality-of-earnings work
Valuation under Rule 11UA for ESOPs, fundraises, and secondary transactions; DCF and comparable-company analysis for MedTech
ESOP design, perquisite-tax computation under Section 17(2), and cap-table maintenance for clinical and engineering talent
Section 56(2)(viib) angel-tax exemption support and DPIIT recognition for MedTech and digital-health startups
Interface with state FDA drug-licensing renewals, NPPA price-control reporting, and Clinical Establishments Act registrations where applicable